CSIMarket Company Name, Ticker, Suppliers, else..
 
Biomerica Inc   (NASDAQ: BMRA)
 
Price: $2.0295 $-0.06 -2.895%
Day's High: $2.1500000953674316 Week Perf: 20.09 %
Day's Low: $ 1.94 30 Day Perf: 32.65 %
Volume (M): 21,241 52 Wk High: $ 3.22
Volume (M$): $ 0 52 Wk Avg: $2.27
Open: $2.15 52 Wk Low: $1.43



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 3
 Employees 50
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Biomerica Inc is a California-based medical diagnostic company that develops, manufactures, and distributes diagnostic tests for various diseases and conditions. The company's products cover a wide range of fields, including gastrointestinal, food intolerance, and diabetes. Biomerica's tests are designed to be easy to use, accurate, and cost-effective, making them suitable for use in both clinical settings and at home. The company's goal is to improve healthcare globally by providing accessible and reliable diagnostic solutions.


   Company Address: 17571 Von Karman Avenue Irvine 92614 CA
   Company Phone Number: 645-2111   Stock Exchange / Ticker: NASDAQ BMRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MYGN   -6.11%    
QDEL   -3.95%    
DGX   -1.58%    
• View Complete Report
   



Stock Market Announcement

Nasdaq Grants Biomerica 180-Day Extension for Listing Compliance Amid Product Development Efforts,

Published Thu, Nov 7 2024 2:09 PM UTC

Biomerica Granted 180-Day Extension by Nasdaq to Regain Listing Compliance Amidst Product ExpansionBiomerica, Inc. (Nasdaq: BMRA), a prominent player in the medical diagnostics industry, has been given a lifeline by the Nasdaq Stock Market LLC with a 180-day extension to comply with its listing requirements. The announcement came on November 7, 2024, providing the company un...
Product Service News

Pioneering a Path to Comfort Biomericas Game-Changing IBS Solution Now Available at Home

Published Mon, Jul 1 2024 11:47 AM UTC

Biomerica Inc., a leading global provider of advanced medical products, has recently unveiled a groundbreaking innovation that promises to significantly improve the lives of millions suffering from Irritable Bowel Syndrome (IBS). The company has launched an at-home sample collection feature for its highly acclaimed inFoods IBS system, aiming to simplify and revolutionize the...
Product Service News

Biomerica Pioneers Groundbreaking Solutions in Medical Diagnostics

Published Mon, May 13 2024 12:19 PM UTC

Biomerica, Inc. continues to push the boundaries of medical diagnostics with recent announcements that demonstrate their commitment to revolutionizing healthcare. The company, which specializes in advanced diagnostic and therapeutic products, has unveiled two significant milestones that have the potential to transform the landscape of medical testing.Firstly, Biomerica recen...
Partnership

Biomerica Inc. and UAE Healthcare Conglomerate Join Forces to Revolutionize Colorectal and Breast Screening

Published Mon, Apr 29 2024 12:19 PM UTC

Biomerica Inc. has recently entered into an exclusive multi-year distribution agreement with a prominent healthcare conglomerate in the United Arab Emirates (UAE). The partnership aims to significantly enhance the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region. This strategic alliance has the potential to revolut...
Management Announcement

Biomerica Defies Odds in Expanding inFoods IBS Platform, Poised to Revolutionize Healthcare

Published Mon, Apr 15 2024 11:47 AM UTC



In an era of increasing public health concerns and escalating medical expenses, Biomerica, a leading global provider of advanced diagnostic products, is making groundbreaking strides in expanding its innovative inFoods platform dedicated to managing and treating Irritable Bowel Syndrome (IBS). With a mission to transform healthcare outcomes for millions of individu...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.33
Price to Sales (Expected) -
Price to Book 2.25
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.53
Working Capital Ratio 1.95
Leverage Ratio (MRQ) 1.57
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.28 $
Revenues (TTM) 1.53 $
Cash Flow (TTM) -
Cash 0.45 $
Book Value 0.9 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 89,060
Net Income per Employee (TTM) -75,500
Receivable Turnover Ratio (TTM) 4.86
Inventory Turnover Ratio (TTM) 2.59
Asset Turnover Ratio (TTM) 0.51

Profitability Ratios Current
Gross Margin (MRQ) -7.88 %
Operating Margin (MRQ) -174.77 %
Net Margin (MRQ) -130.71 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Biomerica Inc's Segments
Clinical Lab    127.51 % of total Revenue
Middle East    1.71 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.